MHRA · NICE · NHS commissioning. Every AXLRx report available for the United Kingdom market.
Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser.
Three NICE technology appraisals (TA606, TA738, TA1101) each carry a confidential Patient Access Scheme, so garadacimab's published £20,625 per-pen price is the only fully transparent figure in the class, and two MHRA-licensed agents still have no NICE-confirmed net price.
The UK Pompe Consortium's shared-care network, a 3–8 year late-onset diagnostic delay, and the ~25% inadequate-ERT-responder subset defining the next-generation enzyme-replacement opportunity.
The UK Pompe Consortium registry counts roughly 200 confirmed patients. Total estimated prevalence, including the undiagnosed pool, runs 350-450. Within the confirmed, treated population, 30-50 are ADA-positive inadequate responders and 80-120 are on home ventilation.
A 37-centre national survey confirms 1,152 UK HAE type I/II patients, a top-down 1:32,000 prevalence rate implies roughly 2,000, and the UK HAE Alliance's broader planning estimate runs to 5,000-6,000, of which only 1,500-2,000 are on prophylaxis today.
A ~4,000-patient UK gMG treatment gap, NHS neuromuscular network diagnostics, and efgartigimod's June 2025 NICE rejection (TA1069) that leaves the access gap unresolved.
The UK SMA population is not one number. A ~1,000-patient actively-monitored NHS cohort and a 1,800-2,000-patient total prevalence estimate both appear across UK sources, and the gap between them is the pre-NBS legacy population outside the four specialist networks' active census.
NICE's rejection-then-reversal of Zolgensma (2021→2023) established a Long-Term Value Framework precedent that now makes one-time gene therapy the NHS's preferred economic choice for newborn-screened SMA infants.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
12,000-15,000 UK gMG patients on the broader estimate, of whom ~4,000 have moderate-severe disease and 2,000-3,000 are refractory, with no NICE-recommended novel agent for any of them.
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000) at the ordinary £20,000–£30,000/QALY bar — the real payer question is how fast NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal.
Why NICE recommended both Dravet therapies through standard Technology Appraisal rather than the ultra-rare HSS route, what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
Oral migalastat versus IV enzyme replacement, and how pegunigalsidase's newly NICE-recommended suboptimal-responder appraisal (TA915) reshapes NHS-commissioned Fabry therapy.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
15,000-17,000 diagnosed UK sickle cell disease patients, universal since 1999 newborn screening, narrow to a 4,000-6,000-patient conventional-therapy gap and a separate 200-300-per-year gene-therapy-eligible pool.
700-900 NHS-diagnosed Fabry patients split cleanly: roughly 600 on enzyme replacement, about 200 (25%) on oral migalastat, and free NHS cascade testing that adds 3-4 diagnosed relatives per index case.
A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.
Why NICE will reject any IgAN submission that isn't built on eGFR slope with mandatory SGLT2i background, the 3,000-5,000 UK patients eligible for a novel agent, and the ESRD-delay cost model that clears the QALY bar.
Avalglucosidase's NICE recommendation (TA821) versus entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.
NICE-commissioned tafamidis access (TA696, updated by TA984), a 30-centre Tc-PYP diagnostic pathway, and vutrisiran's TA868 PAS-backed approval reshaping UK ATTR identification and treatment.
NHS England's Pompe commissioning-policy continuation criteria define a 45-50 patient switch-eligible cohort for avalglucosidase alfa (NICE TA821) — a manageable NHS budget event, while broader first-line uptake would be a materially larger one.
NICE accepts palbociclib, ribociclib, and abemaciclib as comparators for each other. No trial has ever tested any of them head-to-head against exemestane plus everolimus, the older endocrine-based comparator regimen they effectively replaced.
NICE has cleared every modern PNH anti-complement therapy, from ravulizumab to crovalimab, through the standard £20,000-30,000 Technology Appraisal route rather than the more generous Highly Specialised Technologies threshold, each via a confidential patient access scheme.
2,000-2,500 UK Dravet patients, of whom 400-500 are SCN1A-molecularly-confirmed in genetic registries, and 600-900 still inadequately controlled on cannabidiol plus fenfluramine.
True UK ATTRwt-CM prevalence runs 20,000-40,000, and 15,000-36,000 of those patients remain undiagnosed. Only 3,000-4,000 are on NHS-commissioned tafamidis today, adding 1,500-2,000 a year.
England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101), but the two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision.
A ~1,000-patient confirmed UK SMA cohort by type, reconciled against a 1,800-2,000-patient total prevalence estimate, and a 50-60/yr Zolgensma cohort as the on-therapy validation anchor.
Agalsidase beta was never formally appraised by NICE, while migalastat's HST4 recommendation (2016) was the first oral mutation-specific rare disease therapy NICE approved; together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale.
The UK HAE Alliance counts 5,000-6,000 total patients, of whom 1,500-2,000 are on NICE-commissioned prophylaxis. A further 1,500-2,500 are attack-active but never treated, and Longhurst et al.'s 37-centre registry confirms 1,152 patients from the bottom up.
~600-750 UK PNH patients are on active complement-inhibitor therapy against a reconciled total prevalence near 1,500; the other 750-900 are monitored-only or undiagnosed, and this model sizes the gap.
350-450 UK Pompe disease patients, of whom roughly 200 form the registry-confirmed cohort. One in four long-term ERT patients is not holding stable, the segment this model is built to size.
The UK's NICE-commissioned Dravet treatment algorithm manages an estimated 2,000-2,500 patients on cannabidiol and fenfluramine, but the NHS genetic testing registry logs only 400-500 molecularly SCN1A-confirmed cases — a registry-scope gap, not a population contradiction.
Six NHS centres, Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds, and Newcastle, concentrate the UK's refractory Dravet syndrome cohort, and the British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission. That institutional network is what this workbook sizes first, not a roster of named physicians.
Five NHS specialist centres, Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester, manage more than 90% of UK HAE patients. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.
Five named NHS lysosomal storage disorder centres, and Royal Free London's National Fabry Service, named NICE's appointed clinical expert for both migalastat's HST4 and pegunigalsidase alfa's TA915. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
The Renal Association's IgAN guideline committee, not any single physician, sets the clinical reference point NICE checks technology appraisals against. This workbook sizes that committee and the network behind it before individual outreach begins.
A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.
Four London teaching hospitals, Barts, King's, Imperial, and Homerton, anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients, with Birmingham Heartlands, Manchester, Bristol, and Nottingham forming the next concentration ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
A five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network concentrate expertise around a six-physician BIMDG subcommittee that advises NICE directly. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
NICE's SCD gene therapy appraisal, potentially the largest NHS rare disease budget event in history, hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
Five NHS Highly Specialised Services centres, anchored by the Leeds National PNH Service, concentrate fewer than 25 consultants managing over 90% of the UK's PNH caseload. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
NICE's accepted cost-effectiveness case for budesonide (TA937, updated by TA1128) rests on a 5–8 year modelled ESRD delay, and the same mandatory ACEi/ARB gate applied to sparsentan narrows the UK's eligible IgA nephropathy population from 10,000–15,000 to 3,000–5,000 patients.
NICE has never modelled a cost-per-QALY for a myasthenia gravis biologic. Eculizumab's appraisal (TA636) closed before a dossier was submitted; efgartigimod's (TA1069) closed on evidence gaps, not a quantified ICER breach. A new entrant inherits no reusable comparator or price benchmark from either.
NICE accepts a £100,000-300,000 QALY threshold for ultra-rare Pompe disease under its Highly Specialised Technologies pathway, five to fifteen times the £20,000-30,000 bar a standard technology appraisal applies. Avalglucosidase alfa's TA821 recommendation used that ceiling, but only with a substantial confidential commercial arrangement. A new entrant without that leverage should build a standalone case for the antibody-positive inadequate-responder subgroup instead.
Both existing Dravet therapies cleared NICE's standard Technology Appraisal, not the ultra-rare Highly Specialised Technology route. A new entrant's WAC, PAS, and stakeholder-engagement calendar all need to be built against that lower cost-effectiveness bar, with soticlestat's 2026-27 appraisal setting the clock.
UK Renal Registry data, the ACEi/ARB-first Renal Association pathway, and the NHS economic case for novel agents built on £40–50M annual ESRD cost.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
The 600-900 UK Dravet patients still uncontrolled on CBD plus fenfluramine, the cardiac-monitoring burden a REMS-free agent could remove, and the soticlestat clock competing for the same refractory population.
Why a mature 3-drug NICE framework leaves no room for parity entry, the Zolgensma-attenuation and Type 4 adult niches the current agents don't serve, and the NHS gene therapy centre capacity constraint every new gene therapy must plan around.
UK HAE Alliance genetic testing, an 87% attack-rate reduction on lanadelumab, and the NICE TA606 prophylaxis standard defining NHS management.
NICE's June 2025 rejection of efgartigimod (TA1069) leaves UK myasthenia gravis with no NICE-recommended novel agent — eculizumab's own appraisal (TA636) was withdrawn by the manufacturer in 2020 without a cost-effectiveness verdict, and the NHS IVIg cost-offset argument is now the strongest lever for a future resubmission.
Why any new ATTR-CM entrant is judged against tafamidis on NICE's TA984 QALY bar, now joined by acoramidis's TA1121 recommendation, the diagnosis pipeline still leaving 15,000-36,000 UK patients undiagnosed, and why the National Amyloidosis Centre is the single investment that decides the outcome.
Europe's largest SCD population at 15,000–17,000 patients, near-universal newborn-screening diagnosis since 1999, and NICE's recommendation of Casgevy (TA1044) as the gene therapy that will define UK access to a functional cure.
NICE TA606 commissioned lanadelumab with PAS and 87.5% real-world attack reduction — berotralstat's NICE TA738 recommendation is now tested against that same benchmark.
All three UK PNH agents have cleared NICE via the standard Technology Appraisal route: ravulizumab (TA698), iptacopan (TA1000), and crovalimab. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
Two UK gMG estimates disagree by 3-4x on purpose: a narrower moderate-severe subgroup of roughly 4,000 (MGA UK survey) sits inside a broader 12,000-15,000 total prevalence figure that also counts mild, well-controlled cases the narrower estimate excludes.
The Leeds National PNH Registry tracks about 600 UK patients on complement-inhibitor therapy, but AXLRx's own Launch Readiness research cites a broader estimate near 1,500 total patients and 1,000 treated. Reconciling which count anchors a sizing model is the open question.
The EVH-dominant population Ultomiris cannot resolve, the standard NICE Technology Appraisal bar every PNH agent has now cleared, and the PAS discount required to hit it before MHRA approval.
NICE built UK SMA access in sequence: gene therapy took the pre-symptomatic subgroup first (HST15, HST24), then TA1162 moved chronic therapy to routine funding behind it. A new entrant inherits a fixed subgroup hierarchy and a comparator that shifts by population, not an open field.
NICE recommends both ATTR-CM stabilisers, tafamidis (TA984) and acoramidis (TA1121), and directs clinicians to the cheaper one. Acoramidis cleared on indirect comparison alone. A third entrant must beat an invisible, PAS-discounted floor, with no published price target.
Three completed NICE standard technology appraisals already fund HAE prophylaxis in England (TA606, TA738, TA1101), every one cleared at the ordinary £20,000 to £30,000 per QALY bar and held behind a confidential Patient Access Scheme, so a new entrant inherits a comparator-dense field in which garadacimab's £20,625 list pen is the only transparent price.
UK Fabry disease is commissioned through three different NICE and NHS routes at once: no formal NICE technology appraisal for either enzyme replacement therapy, a Highly Specialised Technologies recommendation (HST4, 2016) for migalastat, and a standard technology appraisal (TA915, 2023) for pegunigalsidase alfa. A new entrant inherits no single reusable comparator or price benchmark.
10,000-15,000 UK IgA nephropathy patients, of whom approximately 8,000 are tracked in the UK Renal Registry. Only 3,000-5,000 clear the mandatory ACEi/ARB and SGLT2i optimisation gate to become eligible for a novel agent, and fewer than 500 currently access one pre-NICE.
NICE accepted an eGFR-slope-to-ESRD-delay model, not the headline proteinuria reduction, as the value basis for budesonide (TA937, expanded by TA1128) and sparsentan (TA1074) in IgA nephropathy. The mandatory ACEi/ARB and SGLT2 inhibitor optimisation gate narrows the UK's 10,000 to 15,000 patients to a 3,000 to 5,000 novel-agent-eligible pool before that pricing math applies.
NHS GMS free SCN1A testing, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres running the most treatment-advanced Dravet pathway in Europe.
The NHS lysosomal-storage-disorder specialist network, UK Fabry Outcome Survey longitudinal data, and both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy across an estimated 800-patient UK cohort.
NICE has cleared four modern PNH anti-complement therapies (ravulizumab TA698, pegcetacoplan TA778, iptacopan TA1000 and crovalimab TA1019) through its standard £20,000-30,000 Technology Appraisal route, each contingent on a confidential commercial arrangement, never the Highly Specialised Technologies threshold. A new submission inherits an unbroken standard-STA precedent it must be built to clear from the first dossier decision.
Why the £144M NHS Fabry market, the largest in Europe, already has two established agents, and why an ADA-positive or female-heterozygote niche, not general ERT improvement, is the only viable UK entry point.
NICE recommended crizanlizumab (TA743) via managed access in 2021, then withdrew it in 2023 after the confirmatory trial failed; Casgevy (TA1044) cleared only by restructuring its £1.65M price into managed access. A new entrant inherits no reusable ICER benchmark from either.
Why NICE's rejection of crizanlizumab on price alone is the binding constraint for any new SCD agent, the 4,000-6,000 UK patients left in a post-withdrawal white space, and the WAC ceiling that decides whether you repeat that outcome.
NICE's accepted 20-35% PAS discount off budesonide's WAC sets the pricing floor sparsentan already clears too, against a £140-180M NHS budget ceiling once the ACEi/ARB gate narrows eligibility to 3,000-5,000 patients.
Agalsidase beta runs an estimated £150-250K per patient per year against migalastat's £80-120K, a £70-130K annual switch saving NICE has already quantified but the NHS has not captured at scale, with pegunigalsidase's TA915 commercial arrangement now setting a third price point.
Both NHS-commissioned Dravet therapies cleared NICE's standard £20,000-30,000/QALY bar, not the ultra-rare HSS threshold, so a new entrant is held to the same cost-effectiveness bar the incumbents already cleared. Total NHS Dravet spend still runs a modest £9-16M.
The UK Renal Registry actively tracks about 8,000 IgA nephropathy patients against an estimated 10,000-15,000 total prevalence; only 3,000-5,000 are eligible for a novel agent, and fewer than 500 currently receive one.
700-900 diagnosed UK Fabry patients split roughly 600 ERT to 200 oral, inside which two further niches sit: 50-80 ADA-positive suboptimal responders and 80-120 undertreated symptomatic female heterozygotes, against a £144M NHS spend anchor.
Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture.
NICE's TA1121 cost-minimisation rule directs clinicians to whichever ATTR-CM stabiliser costs less. That rule, not the QALY threshold alone, now sets a new entrant's UK price ceiling.
NICE rejected crizanlizumab at £733K-1.1M per QALY even with a PAS discount. Casgevy cleared only via a 10-year annuity at £165K/year, and any new non-gene agent must land near £15-25K/year to clear that same ceiling.
Why NICE's terminated eculizumab appraisal for gMG remains the price precedent every new asset must clear, the 2,000-3,000 refractory patients with zero NICE-commissioned biologic option, and the IVIg-offset economics that make a launch viable.
The never-prophylaxed growth market lanadelumab leaves open, the PAS discount needed to clear NICE's standard TA bar, and the donidalorsen clock a fast-moving competitor is running against you.
No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.
NHS-commissioned alglucosidase alfa runs £200,000-350,000 per patient a year post-PAS. Avalglucosidase alfa's NICE TA821 recommendation carries a 20-30% WAC premium and a switch-population budget impact of just £2-4M a year.
No UK gMG biologic has ever cleared NICE at any price. Eculizumab's manufacturer withdrew before submitting an ICER, and efgartigimod's June 2025 rejection means a future entrant's price ladder starts from zero precedent, not a benchmark.
Europe's first national SMA newborn-screening programme, all three therapies NICE-recommended with commercial arrangements, and a living UK cohort of ~1,000 patients across four disease types.
NICE TA696 (May 2021, since updated by TA984) opened NHS commissioning of tafamidis for ATTR-CM at scale — acoramidis’s pending appraisal and vutrisiran’s TA868 access route are the two other decisions defining the UK amyloidosis market.
Two novel agents in Named Patient access ahead of NICE decisions — and the £20,000-30,000/QALY standard threshold both must clear, since IgAN doesn't qualify for the ultra-rare HST track.
Near-universal newborn screening puts the UK's 15,000-17,000 SCD patients on the registry with confidence, but only the 4,000-6,000 hydroxycarbamide-inadequate subset is the addressable population for a new non-gene agent.
National Amyloidosis Centre-anchored epidemiology puts UK ATTRwt-CM prevalence at 20,000-40,000. Only 3,000-4,000 patients are on NICE-commissioned tafamidis today, leaving 15,000-36,000 undiagnosed.
Why an ADA-positive-specific NICE case beats competing on incremental FVC improvement against alglucosidase, the 80-120 NIV-dependent LOPD patients who are the highest-urgency target, and the BIMDG partnership that shapes NICE's evidence bar.
NICE rejected Zolgensma in 2021 on cost per QALY, then reversed in 2023 through its Long-Term Value Framework. That framework, not the PAS discount, is the real UK SMA pricing lever, and it sets an estimated £1.2-1.6M net cost against a £4.5-7.5M lifetime chronic-therapy alternative.